Keywords: amylin, start, ph, iii, diabetes, trial, pharmaceuticals

Amylin to start Ph III diabetes trial in 2001

Article | 06 November 2000

Print This

Amylin Pharmaceuticals has moved its second diabetes drug candidate,synthetic exendin-4 (AC2993), into Phase II clinical trials and aims to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in